Elsevier Launches New Journal: International Journal of Paleopathology

By Elsevier, PRNE
Monday, May 30, 2011

OXFORD, England, May 31, 2011 -

- A Dedicated Journal for Collaborations and Cutting-Edge Research in
Paleopathology - Human and Non-Human

Elsevier, a world-leading publisher of scientific, technical and medical
information products and solutions, is pleased to announce the launch of a
new journal, International Journal of Paleopathology, the official journal of
the Paleopathology Association (www.paleopathology.org/). Published
quarterly, the first issue of the journal is now freely available to view
online on SciVerse ScienceDirect (
www.sciencedirect.com/science/journal/18799817). Print copies of the
first issue will be available at the 7th World Congress on Mummy Studies
(associations.sou.edu/aaaspd/2011SANDIEGO/index.html) on 12-16 June
in San Diego, USA, where Elsevier will host a reception to officially
launch the journal.

Editor-in-Chief Professor Jane E. Buikstra of Arizona State University
said, "I am energized by the challenge of creating an academic journal format
that seeks to encourage research and foster interdisciplinary communication.
As the only dedicated paleopathology journal in the community, we are
extremely proud to have the designation of "Official Journal of the
Paleopathology Association".

The International Journal of Paleopathology will publish original and
significant articles on human and animal (including hominids) disease. The
articles are based on the study of physical remains, including osseous,
dental, and preserved soft tissues at a range of methodological levels, from
direct observation to molecular, chemical, histological and radiographic
analysis. Discussion of ways in which these methods can be applied to the
reconstruction of health, disease and life histories in the past is central
to the discipline. This way the journal would also encourage papers covering
interpretive and theoretical issues, and those that place the study of
disease at the centre of a bioarchaeological or biocultural approach.

Papers dealing with historical evidence relating to disease in the past -
rather than with history of medicine - will also be published. The journal
will also accept significant studies that apply previously developed
techniques to new materials, setting the research in the context of current
debates on past human and animal health. Paper types encouraged are original
research articles, case studies, technical notes, brief communications, book
reviews and invited commentaries.

The first issue of the International Journal of Paleopathology is now
freely available to view online on SciVerse ScienceDirect (
www.sciencedirect.com/science/journal/18799817), as well as the first
issue's Welcome Editorial from the Editor-in-Chief, Jane E. Buikstra.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet (www.thelancet.com) and Cell (www.cell.com
), and close to 20,000 book titles, including major reference works from
Mosby and Saunders. Elsevier's online solutions include SciVerse
ScienceDirect (www.sciencedirect.com), SciVerse Scopus (
www.scopus.com), Reaxys (www.reaxys.com), MD Consult
(www.mdconsult.com) and Nursing Consult (www.nursingconsult.com
), which enhance the productivity of science and health professionals, and
the SciVal suite (www.scival.com) and MEDai's Pinpoint Review
(www.medai.com), which help research and health care institutions
deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier (
www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (www.reedelsevier.com), a world-leading
publisher and information provider, which is jointly owned by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

    Media contact

    Lyndsay Scholefield


will not be displayed